UK's Intercytex Buys Stem Cell Group Axordia
This article was originally published in The Pink Sheet Daily
Executive Summary
All-share deal is the only option for AIM-listed Intercytex.
You may also be interested in...
Osiris/Genzyme Put Stem Cells On The Deal Map
First-in-class MSC-based therapy Prochymal headed to regulators in 2009 for GvHD.
The IP Land Grab: New UK Tech Transfer Models
As VCs continue to woo later-stage assets, a new breed of companies has stepped in upstream to help UK universities commercialize their IP. The models vary, and it's unclear how successful they'll be either for investors, or for universities. But the attention and money they're attracting to the area are welcome.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”